Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume

Delayed Quote OTC Markets

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets 00:25:32 02/06/2026 HKT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		-.--%	+9,900.00%

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
22/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 86.92K 81.59K 74.51K 141K 9.66M 141K 966K 374K 4.87M 380K 372K 16.14M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.73M 9.13M 8.34M 15.74M 1.08B 15.81M 108M 41.87M 545M 42.55M 41.63M 1.81B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	89.34%	Yield 2022 *	-	Yield 2023	-

12-29	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
22/10/25	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
14/10/25	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
15/08/25	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
01/05/25	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
30/04/25	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
16/11/24	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
18/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
16/10/24	Top Midday Decliners	MT
15/10/24	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
28/09/24	Top Midday Decliners	MT
25/09/24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
25/09/24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

21/09/23	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
21/09/23	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
21/09/23	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
16/05/23	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
24/03/23	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

22/11/24	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
25/10/24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
25/10/24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
15/10/24	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
15/10/24	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

Current year	0		0.01
1 year	0		0.01
3 years	0		4,665.6
5 years	0		10,713.61
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	01/01/2019
Michael Golembiewski DFI	Director of Finance/CFO	54	01/09/2021
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
29/2/24	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
12/1/24	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%
12/1/24	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	-.--%	+9,900.00%	-100.00%	136
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	71.35B
ARGENX SE	+2.09%	+2.28%	+49.95%	+91.30%	64.17B
BIONTECH SE	-1.31%	-0.50%	+7.41%	-4.29%	28.65B
INSMED INCORPORATED	+0.40%	-4.80%	-5.89%	+469.55%	27.06B
WUXI BIOLOGICS (CAYMAN) INC.	-1.28%	+0.73%	+57.43%	+10.50%	27.33B
GENMAB A/S	-1.68%	+0.33%	+36.86%	-16.09%	20.47B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	19.36B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.58%	-1.78%	+12.97%	+542.33%	15.96B
EXELIXIS, INC.	-1.09%	+3.14%	+46.32%	+155.12%	14.05B
Average	+990.18%	+3.65%	+1,043.55%	+167.24%	28.84B
Weighted average by Cap.	+0.98%	+3.29%	+55.52%	+155.23%

	2022	2023
Net sales	-	2.2 1.89 1.77 1.62 3.06 210.12 3.07 21 8.14 106 8.27 8.09 351.09
Net income	-73.53M -63.11M -59.24M -54.1M -102M -7.01B -103M -701M -272M -3.54B -276M -270M -11.72B	-37.88M -32.51M -30.52M -27.87M -52.6M -3.61B -52.86M -361M -140M -1.82B -142M -139M -6.04B
Net Debt	4.59M 3.94M 3.7M 3.38M 6.37M 438M 6.4M 43.75M 16.95M 221M 17.23M 16.86M 731M	11.23M 9.64M 9.05M 8.26M 15.6M 1.07B 15.67M 107M 41.5M 540M 42.17M 41.26M 1.79B